Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

Mukesh Kumar, Vinicius Ernani, Taofeek K. Owonikoko

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining characteristics of these NSCLC subtypes have evolved into important tools for prognosis and for predicting the likelihood of benefit when patients are treated with anticancer agents.

Original languageEnglish (US)
Pages (from-to)55-66
Number of pages12
JournalMolecular Aspects of Medicine
Volume45
DOIs
StatePublished - Apr 6 2015
Externally publishedYes

Fingerprint

Biomarkers
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Cells
Small Cell Lung Carcinoma
Antineoplastic Agents
Genomics
Set theory
Therapeutics
Growth
Neoplasms

Keywords

  • ALK
  • Biomarkers
  • EGFR
  • Lung cancer
  • NSCLC
  • RET
  • ROS1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. / Kumar, Mukesh; Ernani, Vinicius; Owonikoko, Taofeek K.

In: Molecular Aspects of Medicine, Vol. 45, 06.04.2015, p. 55-66.

Research output: Contribution to journalReview article

@article{c69f1fafcf574667b312ece852e1b4f7,
title = "Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer",
abstract = "The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining characteristics of these NSCLC subtypes have evolved into important tools for prognosis and for predicting the likelihood of benefit when patients are treated with anticancer agents.",
keywords = "ALK, Biomarkers, EGFR, Lung cancer, NSCLC, RET, ROS1",
author = "Mukesh Kumar and Vinicius Ernani and Owonikoko, {Taofeek K.}",
year = "2015",
month = "4",
day = "6",
doi = "10.1016/j.mam.2015.06.009",
language = "English (US)",
volume = "45",
pages = "55--66",
journal = "Molecular Aspects of Medicine",
issn = "0098-2997",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

AU - Kumar, Mukesh

AU - Ernani, Vinicius

AU - Owonikoko, Taofeek K.

PY - 2015/4/6

Y1 - 2015/4/6

N2 - The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining characteristics of these NSCLC subtypes have evolved into important tools for prognosis and for predicting the likelihood of benefit when patients are treated with anticancer agents.

AB - The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining characteristics of these NSCLC subtypes have evolved into important tools for prognosis and for predicting the likelihood of benefit when patients are treated with anticancer agents.

KW - ALK

KW - Biomarkers

KW - EGFR

KW - Lung cancer

KW - NSCLC

KW - RET

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=84946489325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946489325&partnerID=8YFLogxK

U2 - 10.1016/j.mam.2015.06.009

DO - 10.1016/j.mam.2015.06.009

M3 - Review article

VL - 45

SP - 55

EP - 66

JO - Molecular Aspects of Medicine

JF - Molecular Aspects of Medicine

SN - 0098-2997

ER -